Sutro Biopharma, Inc. is a public biotechnology company based in South San Francisco, California, specializing in clinical stage drug discovery, development, and manufacturing. Utilizing its innovative XpressCF platform, the company focuses on creating protein therapeutics for cancer and autoimmune disorders, including cytokine-based immune-oncology therapeutics and bispecific antibodies.
The company's product candidates, STRO-001 and STRO-002, are antibody-drug conjugates designed to target specific cancer markers such as CD74 and folate receptor-alpha, offering promising treatment options for patients with multiple myeloma, non-Hodgkin lymphoma, ovarian, and endometrial cancers.
Generated from their website's infomation